The serum tryptase test: An emerging robust biomarker in clinical hematology

Expert Review of Hematology

Volumn 7, Issue 5, 2014, Pages 683-690

  Valent, Peter ^a   Sperr, Wolfgang R ^a   Sotlar, Karl ^b   Reiter, Andreas ^c   Akin, Cem ^d   Gotlib, Jason ^e   Horny, Hans Peter ^b   Arock, Michel ^f  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e STANFORD CANCER INSTITUTE   (United States)

^f Ecole Normale Superieure de Cachan   (France)

Author keywords

biomarker; mastocytosis; myeloid leukemias; prognostication; tryptase

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; TRYPTASE; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; BASOPHIL; BASOPHILIA; BLOOD EXAMINATION; BONE MARROW EXAMINATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CHRONIC EOSINOPHILIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; DIAGNOSTIC TEST; ENZYME BLOOD LEVEL; EOSINOPHILIC LEUKEMIA; HEMATOLOGIC DISEASE; HEMATOLOGICAL PARAMETERS; HEMATOLOGY; HUMAN; KARYOTYPE; MAST CELL; MULTIPLE MYELOMA; MYELOPROLIFERATIVE NEOPLASM; PHILADELPHIA CHROMOSOME POSITIVE CELL; PREDICTIVE VALUE; RECURRENCE FREE SURVIVAL; REVIEW; SEROLOGY; SERUM; SERUM TRYPTASE TEST; STEM CELL TRANSPLANTATION; SYSTEMIC MASTOCYTOSIS; BLOOD; GENETICS; LEUKEMIA, MYELOID; MASTOCYTOSIS; METABOLISM; MORTALITY; PROGNOSIS;

BIOLOGICAL MARKERS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID; MAST CELLS; MASTOCYTOSIS; PROGNOSIS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TRYPTASES;

EID: 84907062161     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2014.955008     Document Type: Review

References (78)

1. Druker BJ. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 2002;21(56):8541-6
2. Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009;113(8):1619-30
3. Yeung DT, Hughes TP. Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia. Crit Rev Oncog 2012;17(1):17-30
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352(17):1779-90
5. Tefferi A, Lasho TL, Schwager SM, et al. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 2005;131(3):320-8
6. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369(25):2379-90
7. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995;92(23):10560-4
8. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12(3): 312-14
9. Bodemer C, Hermine O, Palmérini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010; 130(3):804-15
10. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348(13):1201-14
11. Cross NC, Reiter A. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol 2008;119(4):199-206
12. Bain BJ. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Haematologica 2010;95(5):696-8
13. Bacher U, Haferlach T, Kern W, et al. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 2007;92: 744-52
14. Bacher U, Schnittger S, Haferlach T. Molecular genetics in acute myeloid leukemia. Curr Opin Oncol 2010;22(6): 646-55
15. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011;29(5): 475-86
16. Greenberg PL. Molecular and genetic features of myelodysplastic syndromes. Int J Lab Hematol 2012;34(3):215-22
17. Lindsley RC, Ebert BL. The biology and clinical impact of genetic lesions in myeloid malignancies. Blood 2013;122(23):3741-8
18. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood 2013;122(25): 4021-34
19. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012;481(7382):506-10
20. Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012;366(12): 1090-8
21. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012;150(2):264-78
22. Schwaab J, Schnittger S, Sotlar K, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013;122(14):2460-6
23. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012;44(11): 1179-81
24. Biernaux C, Loos M, Sels A, et al. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995;86(8): 3118-22
25. Corces-Zimmerman MR, Hong WJ, Weissman IL, et al. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA 2014; 111(7):2548-53
26. Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014;506:328-33
27. Valent P, Bonnet D, De Maria R, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012;12(11):767-75
28. Sperr WR, El-Samahi A, Kundi M, et al. Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest 2009; 39(10):914-23
29. Cairoli R, Ripamonti CB, Beghini A, et al. Total serum tryptase: a predictive marker for KIT mutation in acute myeloid leukemia. Leuk Res 2009;33(9):1282-4
30. Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012;157(3):215-25
31. Schwartz LB, Lewis RA, Seldin D, Austen KF. Acid hydrolases and tryptase from secretory granules of dispersed human lung mast cells. J Immunol 1981;126(4): 1290-4
32. Schwartz LB, Irani AM, Roller K, et al. Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J Immunol 1987;138(8):2611-15
33. Castells MC, Irani AM, Schwartz LB. Evaluation of human peripheral blood leukocytes for mast cell tryptase. J Immunol 1987;138(7):2184-9
34. Miller JS, Westin EH, Schwartz LB. Cloning and characterization of complementary DNA for human tryptase. J Clin Invest 1989;84(4):1188-95
35. Vanderslice P, Ballinger SM, Tam EK, et al. Human mast cell tryptase: multiple cDNAs and genes reveal a multigene serine protease family. Proc Natl Acad Sci USA 1990; 87(10):3811-15
36. Miller JS, Moxley G, Schwartz LB. Cloning and characterization of a second complementary DNA for human tryptase. J Clin Invest 1990;86(3):864-70
37. Schwartz LB, Min HK, Ren S, et al. Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells. J Immunol 2003;170(11): 5667-73
38. Dvorak AM, Schleimer RP, Lichtenstein LM. Human mast cells synthesize new granules during recovery from degranulation. In vitro studies with mast cells purified from human lungs. Blood 1988;71(1):76-85
39. Jogie-Brahim S, Min HK, Fukuoka Y, et al. Expression of alpha-tryptase and beta-tryptase by human basophils. J Allergy Clin Immunol 2004;113(6):1086-92
40. Samorapoompichit P, Kiener HP, Schernthaner GH, et al. Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood 2001; 98(8):2580-3
41. Schwartz LB, Sakai K, Bradford TR, et al. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest 1995;96(6):2702-10
42. Lin RY, Schwartz LB, Curry A, et al. Histamine and tryptase levels in patients with acute allergic reactions: an emergency department-based study. J Allergy Clin Immunol 2000;106(1 Pt 1):65-71
43. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006;26(3):451-63
44. Schwartz LB, Metcalfe DD, Miller JS, et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987;316(26): 1622-6
45. Schwartz LB, Bradford TR, Rouse C, et al. Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. J Clin Immunol 1994; 14(3):190-204
46. Schwartz LB. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res 2001;25(7):553-62
47. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25(7):603-25
48. Valent P, Horny H-P, Li CY, et al. Mastocytosis (mast cell disease). In: World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Editors Jaffe ES, Harris NL, Stein H, Vardiman JW, IARC Press; Lyon, France: 2001. pp 291-302
49. Horny HP, Akin C, Metcalfe DD, et al. Mastocytosis (mast cell disease). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. World Health Organization (WHO) classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. IARC Press; Lyon, France: 2008. pp 54-63
50. Sperr WR, Jordan JH, Baghestanian M, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001;98(7): 2200-9
51. Horny HP, Sotlar K, Stellmacher F, et al. The tryptase positive compact round cell infiltrate of the bone marrow (TROCIBM): a novel histopathological finding requiring the application of lineage specific markers. J Clin Pathol 2006;59(3):298-302
52. Sperr WR, Mitterbauer M, Mitterbauer G, et al. Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse. Clin Cancer Res 2005;11(18):6536-43
53. Sperr WR, Stehberger B, Wimazal F, et al. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma 2002;43(5):1097-105
54. Schliemann S, Seyfarth F, Hipler UC, Elsner P. Impact of age and heterophilic interference on the basal serum tryptase, a risk indication for anaphylaxis, in 1,092 dermatology patients. Acta Derm Venereol 2012;92(5):484-9
55. van Toorenenbergen AW, van Daele PL, Boonstra JG. False-elevated serum tryptase assay result caused by heterophilic antibodies. J Allergy Clin Immunol 2005; 116(5):1159-60
56. Sargur R, Cowley D, Murng S, et al. Raised tryptase without anaphylaxis or mastocytosis: heterophilic antibody interference in the serum tryptase assay. Clin Exp Immunol 2011;163(3):339-45
57. Dugas-Breit S, Schöpf P, Dugas M, et al. Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus. J Dtsch Dermatol Ges 2005;3(5):343-7
58. Sirvent AE, González C, Enríquez R, et al. Serum tryptase levels and markers of renal dysfunction in a population with chronic kidney disease. J Nephrol 2010;23(3): 282-90
59. Roche-Lestienne C, Lepers S, Soenen-Cornu V, et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 2005; 19(5):792-8
60. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003;101(12):4660-6
61. Jaafari-Ashkavandi Z, Khademi B, Akbari S, Malekzadeh M. Serum level of mast cell tryptase in patients with oral squamous cell carcinoma: lack of correlation with clinicopathologic factors. Asian Pac J Cancer Prev 2013;14(5):2955-8
62. Goffredo V, Gadaleta CD, Laterza A, et al. Tryptase serum levels in patients suffering from hepatocellular carcinoma undergoing intra-arterial chemoembolization: possible predictive role of response to treatment. Mol Clin Oncol 2013;1(2):385-9
63. Ammendola M, Sacco R, Sammarco G, et al. Correlation between serum tryptase, mast cells positive to tryptase and microvascular density in colo-rectal cancer patients: possible biological-clinical significance. PLoS One 2014;9(6):e99512
64. Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol 2004;114(1):3-11
65. Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009;123(3):680-6
66. Alvarez-Twose I, Zanotti R, González-de-Olano D, et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol 2014;133(2):520-8
67. Valent P, Escribano L, Broesby-Olsen S, et al. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European competence network on mastocytosis. Allergy 2014;In press
68. Sperr WR, Jordan JH, Fiegl M, et al. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol 2002;128(2):136-41
69. Valent P, Akin C, Sperr WR, et al. Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression. Int Arch Allergy Immunol 2002;127(2):137-9
70. Jordan JH, Fritsche-Polanz R, Sperr WR, et al. A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. Leuk Res 2001;25(7):627-34
71. Bernd HW, Sotlar K, Lorenzen J, et al. Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature. J Clin Pathol 2004;57(3):324-8
72. Fritsche-Polanz R, Fritz M, Huber A, et al. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. Mol Oncol 2010;4(4):335-46
73. Johnson RC, Savage NM, Chiang T, et al. Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol 2013;140(4):525-35
74. Sperr WR, Walchshofer S, Horny HP, et al. Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val. Br J Haematol 1998;103(3):740-9
75. Valent P, Agis H, Sperr W, et al. Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia. Leuk Lymphoma 2008;49(4):635-8
76. Florian S, Esterbauer H, Binder T, et al. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leuk Res 2006; 30(9):1201-5
77. Schmitt-Graeff AH, Erben P, Schwaab J, et al. The FIP1L1-PDGFRA fusion gene and the KIT D816V mutation are coexisting in a small subset of myeloid/ lymphoid neoplasms with eosinophilia. Blood 2014;123(4):595-7
78. Sabato V, Van De Vijver E, Hagendorens M, et al. Familial hypertryptasemia with associated mast cell activation syndrome. J Allergy Clin Immunol 2014;In press